Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Xyrem for the treatment of cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Defitelio to treat severe veno-occlusive disease; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab in Phase 3 trial to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Epidiolex in Phase 3 trial to treat LGS, DS, and TSC; Suvecaltamide in Phase 2 trial to treat Parkinson's disease tremor; JZP815, a pan-RAF kinase inhibitor in Phase 1 trial that targets components of the mitogen-activated protein kinase; JZP898, a conditionally activated interferon alpha molecule in Phase 1 trial; JZP441 in Phase 1 trial to treat narcolepsy, IH, and other sleep disorders; JZP324, an extended-release low sodium oxybate formulation in Phase 1 trial for patients with sleep disorders; and JZP150 to treat post-traumatic stress disorder. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Jazz Pharmaceuticals plc

Wells Fargo analyst Mohit Bansal assigned a Buy rating to Jazz Pharmaceuticals yesterday and set a price target of $300.00. Bansal covers the Healt...

Jazz Pharmaceuticals (JAZZ) Receives a Buy from Wells Fargo

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HealthStream (HSTM) and Jazz Pharmaceuticals (JAZZ) ...

Analysts Offer Insights on Healthcare Companies: HealthStream (HSTM) and Jazz Pharmaceuticals (JAZZ)

Jazz Pharmaceuticals ($JAZZ) announced an update on their ongoing clinical study. Jazz Eyes Adult LGS Opportunity With New CBD Study. Jazz Pharmace...

Jazz Pharmaceuticals Targets Adult LGS Growth With New Cannabidiol Dosing Study

Jazz Pharmaceuticals ( ($JAZZ) ) has issued an update. At its July 23, 2026 annual general meeting in Dublin, Jazz Pharmaceuticals’ shareholders el...

Jazz Pharmaceuticals Shareholders Reaffirm Board and Governance Plans

Jazz Pharmaceuticals ($JAZZ) announced an update on their ongoing clinical study. Jazz Pharmaceuticals is running a Phase 2 study called “A Phase 2...

Jazz Targets Lung Cancer Growth With New Lurbinectedin–Durvalumab Trial

Analysts are intrested in these 5 stocks: ( ($JAZZ) ), ( ($AAPL) ), ( ($AEP) ), ( ($MCO) ) and ( ($MMM) ). Here is a breakdown of their recent


Apple, Jazz, Moody’s, AEP, 3M Trending With Analysts

In a report released today, from Jefferies maintained a Buy rating on Jazz Pharmaceuticals, with a price target of $282.00. Jazz Pharmaceuticals ha...

Jazz Pharmaceuticals (JAZZ) Receives a Buy from Jefferies

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Tecan Group AG (TCHBF) and Jazz Pharmaceuticals (JAZ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	JAZZ	$256.56	-0.04%	970.71K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	JAZZ	$256.56	-0.0%	970.71K
3
4
5
6

JAZZ

JAZZ

Get Jazz Pharmaceuticals plc Data in Excel

Get Jazz Pharmaceuticals plc Data in Excel